Heterocyclic Molecular Targeted Drugs and Nanomedicines for Cancer: Recent Advances and Challenges

被引：5

作者：

Liu, Junxia ^{[1
]}

Chao, Tengfei ^{[1
]}

Liu, Yingying ^{[2
,3
]}

Gong, Chen ^{[1
]}

Zhang, Yinan ^{[4
]}

Xiong, Huihua ^{[1
]}

机构：

[1] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Oncol, Wuhan 430000, Peoples R China

[2] Shanghai Jiao Tong Univ, Frontiers Sci Ctr Transformat Mol, Sch Chem & Chem Engn, Shanghai 200000, Peoples R China

[3] Shanghai Jiao Tong Univ, Natl Ctr Translat Med, Shanghai 200000, Peoples R China

[4] Tongji Univ, Sch Chem Sci & Engn, Shanghai 200000, Peoples R China

来源：

PHARMACEUTICS | 2023年 / 15卷 / 06期

关键词：

heterocyclic compounds; molecular targeted drugs; nanomedicine; cancer; NITRIC-OXIDE; BREAST-CANCER; TUMOR ANGIOGENESIS; C-MET; MDMX; P53; VANDETANIB; DELIVERY; AGENT; CELLS;

D O I：

10.3390/pharmaceutics15061706

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Cancer is a top global public health concern. At present, molecular targeted therapy has emerged as one of the main therapies for cancer, with high efficacy and safety. The medical world continues to struggle with the development of efficient, extremely selective, and low-toxicity anticancer medications. Heterocyclic scaffolds based on the molecular structure of tumor therapeutic targets are widely used in anticancer drug design. In addition, a revolution in medicine has been brought on by the quick advancement of nanotechnology. Many nanomedicines have taken targeted cancer therapy to a new level. In this review, we highlight heterocyclic molecular-targeted drugs as well as heterocyclic-associated nanomedicines in cancer.

引用

页数：18

共 117 条

[1] Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein [J].